The Community Oncology Alliance (COA) filed an Amicus Curiae brief with the United States Court of Appeals for the Seventh Circuit warning that contract pharmacies affiliated with pharmacy benefit managers (PBMs) have taken over and mutated the 340B Drug Pricing Program. In addition to diverting 340B discounts from patients in need, lucrative for-profit PBM contract pharmacy arrangements are fueling the broader PBM takeover of the nation’s pharmaceutical system which harms all Americans through higher drug costs and unacceptable barriers to accessible, affordable health care.
The case is Eli Lilly and Company et al. v. Xavier Becerra et al., case number 21-3128, in the U.S. Court of Appeals for the Seventh Circuit.
COA Amicus Brief in 340B Contract Pharmacy Dispute
The Community Oncology Alliance (COA) filed an Amicus Curiae brief with the United States Court of Appeals for the Seventh Circuit warning that contract pharmacies affiliated with pharmacy benefit managers (PBMs) have taken over and mutated the 340B Drug Pricing Program. In addition to diverting 340B discounts from patients in need, lucrative for-profit PBM contract pharmacy arrangements are fueling the broader PBM takeover of the nation’s pharmaceutical system which harms all Americans through higher drug costs and unacceptable barriers to accessible, affordable health care.
The case is Eli Lilly and Company et al. v. Xavier Becerra et al., case number 21-3128, in the U.S. Court of Appeals for the Seventh Circuit.